VGLL1: A Potential Drug Target and Biomarker (G51442)

Target Name: VGLL1

NCBI ID: G51442

VGLL1

VGLL1: A Potential Drug Target and Biomarker

Vestigial like gene 1 (VGLL1) is a non-coding RNA molecule that has been identified in various organisms, including humans. VGLL1 is known to play a crucial role in the development and progression of various diseases, including cancer. Its unique structure and function have made it an attractive target for drug development. In this article, we will discuss the potential of VGLL1 as a drug target and biomarker.

Potential Drug Target

VGLL1 has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. It has been shown to play a role in the development of cancer by promoting the growth of cancer cells, inhibiting apoptosis, and increasing inflammation. Therefore, VGLL1 is a potential drug target for cancer treatment.

One of the main compounds that have been shown to interact with VGLL1 is 5-fluorouracil (5-FU). 5-FU is an anti-cancer drug that is commonly used to treat various cancers, including colon cancer. Studies have shown that VGLL1 can be regulated by 5-FU, and that inhibition of VGLL1 activity can lead to reduced 5-FU sensitivity in cancer cells. Therefore, VGLL1 may be an effective drug target for cancer treatment.

Biomarker

VGLL1 has also been shown to be involved in the regulation of various biological processes, including cell apoptosis. Therefore, it may be a useful biomarker for the diagnosis and prognosis of certain diseases.

Studies have shown that VGLL1 is involved in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. During apoptosis, VGLL1 has been shown to promote the release of stress granules, which contain various cellular stress-related proteins. These proteins can cause cellular damage and contribute to the development of certain diseases.

In addition, VGLL1 has been shown to regulate the expression of genes involved in cell apoptosis. This suggests that VGLL1 may be involved in the regulation of cellular processes that are important for the maintenance of cellular health and homeostasis.

Conclusion

In conclusion, VGLL1 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Its unique structure and function make it an attractive target for drug development. The potential of VGLL1 as a drug target and biomarker make it a promising compound for the development of new treatments for various diseases. Further research is needed to fully understand the role of VGLL1 in disease progression and the development of new treatments.

Protein Name: Vestigial Like Family Member 1

Functions: May act as a specific coactivator for the mammalian TEFs

The "VGLL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VGLL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets